The publisher explores Daiichi Sankyo’s prescription pharmaceutical performance and outlook over 2019-29.
Snapshot
Model updates (30 October 2020)
Model updates (31 January 2020)
Model updates (31 October 2019)
Model updates (14 August 2019)
Snapshot
- Overview - Daiichi Sankyo is forecast to show strong growth through 2026 due to oncology drug Enhertu.
- Key themes - [1] Daiichi Sankyo’s pipeline is looking very fruitful due to Enhertu [2] Enhertu is projected to reach over $2bn in sales by 2025, and will continue to grow further. It is more than capable of offsetting generic pressure from longer-listed products and increasing Daiichi Sankyo’s topline revenue [3] Daiichi Sankyo will look to use knowledge gained from Enhertu to expand its presence in the oncology field.
Model updates (30 October 2020)
- Enhertu forecast adjusted higher due to strong launch trends in the US
- Tarlige forecast adjusted higher
- Lixiana forecast adjusted lower.
Model updates (31 January 2020)
- DS-8201 launch expedited
- Mirogabalin forecast adjusted higher due to launch progression
- Memary forecast adjusted higher.
Model updates (31 October 2019)
- Movantik forecast removed due to being transferred to AstraZeneca
- MorphaBond forecast removed due to cancellation of sales agreement
- RoxyBond forecast removed due to cancellation of sales agreement
- DS-8201 Japan launch expedited
- Quizartinib US and 5EU launch delayed
- Injectafer US patent expiry added for 2027
- Lixiana forecast adjusted higher due to sales expansion in Japan
- Injectafer forecast adjusted higher due to raised company guidance.
Model updates (14 August 2019)
- Savaysa/Lixiana forecast adjusted higher due to company guidance
- Loxonin forecast adjusted lower due to generic competition
- Olmesartan forecast adjusted higher due to company guidance
- Nexium forecast adjusted higher due to company guidance
- Canalia forecast adjusted higher due to strong launch
- Vimpat forecasted adjusted higher due to launch results
- Welchol forecast adjusted lower due to company guidance
- Movantik forecast adjusted lower due to generic competition
- DS-8201 forecast added.
Table of Contents
Company Background
Company Forecast
Company Profile
Clinical Trial Overview
